Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- AI Disrupts the Graphite Value Chain: From Mining to Battery Recycling, Intelligent Systems Are Reshaping a Critical Materials MarketReport highlights how AI improves graphite production efficiency and material performance as demand grows across batteries, electrodes and industrial uses.
- NOAA Publishes TMC USA’s Consolidated Application for an Exploration License and Commercial Recovery Permit for TMC USA-A in the Federal RegisterTMC the metals company Inc. (Nasdaq: TMC) (“TMC”, “The Metals Company” or the “Company”), a leading developer of the world’s largest resource of critical metals essential to energy, defense, manufacturing and infrastructure, today announced that the National Oceanic and Atmospheric Administration (“NOAA”) published in the Federal Register the consolidated application submitted by the Company’s subsidiary, The Metals Company USA LLC (“TMC USA”), for an exploration license and commercial recovery permit for TMC USA-A under the Deep Seabed Hard Mineral Resources Act (“DSHMRA”) and its implementing regulations.
- aPriori TechnologiesaPriori Technologies Launches aiSource, Giving Procurement Teams the Manufacturing Product Intelligence to Negotiate on Equal Terms with SuppliersCONCORD, Mass., August 19, 2026--aPriori launches aiSource, closing the expertise gap in supplier negotiations, giving every buyer the intelligence to negotiate on equal terms.
- YFOREYFORE Unveils New North America Headquarters and Facility in AtlantaThe August 26 grand opening brings local R&D, advanced manufacturing, and supply chain capabilities directly to regional OEM partners. — YFORE, a global Tier 1 automotive electronics supplier specializing in intelligent mobility, will celebrate the...
- Homerun Resources Inc.Homerun Resources Inc. Announces Strategic MOU with Cebrace Brazil's Largest Float Glass ManufacturerHomerun Resources Inc. (TSXV: HMR) (OTCQB: HMRFF) ("Homerun" or the "Company") is pleased to announce the execution of a Memorandum of Understanding ("MOU") with Cebrace Cristal Plano Ltda. ("Cebrace"), Brazil's leading float glass manufacturer, to evaluate a strategic commercial partnership supporting the development of Homerun's Solar Glass Manufacturing Facility in Bahia, Brazil. Cebrace is a joint venture between Saint-Gobain...
- zSpace, Inc.Big Bend Technical College Preps Students for Industry 4.0 with zSpace AR/VRTaylor County Schools' technical college pairs immersive robotics and manufacturing training with a new Advanced Manufacturing facility; free webinar set for August 25
- Statetron presenta Andromean Class™Una nueva era de industrualización Qatar 2030: Statetron presenta un nuevo plan estratégico para una industria autónoma, inteligente y con energía propia DOHA, Qatar, 19 de agosto de 2026 -- Statetron presenta hoy Andromean Class™, una nueva arquitectura industrial diseñada...
- STATETRON INTRODUCES ANDROMEAN CLASS™A NEW ERA OF INDUSTRIALISATION Qatar 2030: Statetron unveils a new blueprint for autonomous, intelligent and energy-native industry — Statetron today introduces Andromean Class™, a new industrial architecture designed to usher in a new era of...
- Guoquan (2517.HK) 2026 Interim Results: Dual Growth in Scale and Efficiency, Powered by the Dual Drivers of Membership Stickiness and Product MatrixGuoquan Food (Shanghai) Co., Ltd. ("Guoquan" or the "Company"; stock code: 2517.HK), a leading one-stop home meal products brand in China, announced its interim results for the six months ended 30 June 2026, which have been reviewed by the Audit and Risk Management Committee of the Board. For the six months ended 30 June 2026, Guoquan recorded a revenue of RMB3,946.9 million, representing a year-on-year increase of 21.8%; gross profit was RMB848.6 million, representing a year-on-year increase of 18.3%, with gross profit margin of 21.5%, compared to 22.1% for the first half of 2025. Net profit for the period was RMB213.2 million, representing a year-on-year increase of 12.1%; core operating profit (non-IFRS measure) was RMB225.0 million, representing a year-on-year increase of 18.3%; and basic and diluted earnings per share were RMB0.0807, representing a year-on-year increase of 18.0%. Against the backdrop of a generally prudent macro consumption environment, the resilience of Guoquan's business model was further demonstrated, underpinned by its rigid-demand attributes and value-for-money positioning. Firmly advancing the "community central kitchen" strategy, the Company achieved double-digit growth in both revenue and core operating profit through the continuous expansion and refined operation of its omni-channel instant retail network, with the number of registered members reaching approximately 82.0 million, further consolidating its leading position in the home-dining retail market. Omni-channel Network Expansion Accelerated, with Scale and Store Efficiency Improving in Tandem As at 30 June 2026, Guoquan's total store count increased to 12,198, representing a net addition of 1,798 stores compared to the same period last year, covering 31 provinces, autonomous regions and municipalities in the Chinese Mainland, as well as the Hong Kong Special Administrative Region of the PRC. During the Reporting Period, the Company added 997 operating stores and reduced 365 operating stores, representing a net addition of 632 stores. Among them, township-level stores recorded a net increase of 367 to 3,377, further enhancing penetration in lower-tier markets. Store efficiency improvement and store format innovation advanced in tandem. During the Reporting Period, in addition to 24-hour unmanned retail stores, the Company completed large-store format upgrades for 684 stores which, leveraging the presentation of an enriched product portfolio and the creation of all-day consumption scenarios, effectively drove the growth of store sales; 96 Guoquan camping stores commenced operation, covering emerging consumption scenarios such as outdoor gatherings and countryside leisure. Revenue from sales of products to existing franchised stores was RMB2,581.5 million in the first half of 2026, representing a year-on-year increase of 7.4%. For online-offline synergy, Guoquan relied on its Guoquan APP, WeChat mini-program, third-party food delivery platforms and social commerce platforms such as Douyin to drive deep integration between offline stores and online channels. The Company achieved over 6.97 billion impressions on platforms through its multi-level Douyin accounts matrix, representing a year-on-year increase of 117.8%; stores generated GMV of RMB910 million via the Douyin channel, representing a year-on-year increase of 97.2%. Through a multi-channel, multi-scenario layout and the deep integration of online and offline operating models, Guoquan successfully established a holistic instant retail store network, providing consumers with the "Guoquan Instant Commerce" shopping experience. Dual Drivers of Membership Ecosystem and Product Matrix Significantly Strengthened Consumer Stickiness As at 30 June 2026, the number of Guoquan's registered members reached approximately 82.0 million, representing a year-on-year increase of 63.0%. More importantly, during the Reporting Period, the consumption amount of members accounted for 73.2% of the Company's total sales, representing a substantial year-on-year increase of 12 percentage points, demonstrating the effectiveness of the Company's membership program in building close online and offline connections and engagement with consumers and fostering consumer loyalty. The simultaneous growth in membership scale and consumption share provides a high-quality existing customer base for the Company's revenue growth. On the product front, during the Reporting Period, the Company introduced a total of 139 new SKUs of hotpot and barbecue products, and successively launched or upgraded a number of scenario-based set meal products such as "Barbecue Camping Container Set", "Chongqing Wanzhou Grilled Fish Pot" and "Crayfish Freedom Bucket"; around the drinks and beverage scenario, it launched a variety of NFC fruit juices, craft beer and flavored tea beverages, further enriching its one-stop meal offerings. Guoquan Farm delivered an outstanding performance, achieving an omnichannel paid GMV of RMB240.0 million during the Reporting Period through online channels such as Douyin livestreaming, representing a year-on-year increase of more than 600%, and newly launched a variety of new SKUs such as Monthong durian pulp, tiger skin durian mille-feuille cake, Beihai Cooked Salted Sea Duck Eggs and crispy mini ice cream, further improving the all-scenario product layout. Deepened Supply Chain and Industrial Layout Supports Scaled Development On the industrial front, Guoquan continued to promote the integrated closed-loop construction of "production, supply and marketing". As at 30 June 2026, the Company had a total of seven food ingredient production plants, covering core categories such as condiments, meatballs, paste and aquatic products, and beef products, forming a comprehensive and well-defined production capacity matrix; the food production base in Danzhou, Hainan Province is commencing construction, which upon completion will further expand its geographical coverage and optimise the supply chain's radiation radius. The Company's bargaining power in upstream procurement has been continuously enhanced, while economies of scale on the production side continued to be unlocked, providing support for cost optimisation. Digital supply chain management was deepened in parallel. Cooperating with warehousing and logistics suppliers and leveraging 21 digitalized central warehouses across China, Guoquan achieved swift circulation of products through digital stock and barcode management, with most orders delivered the next day from central warehouses to retail stores. Supply chain digitalisation covers all core segments including production, procurement, warehousing and logistics, enabling the Company to monitor supply and demand dynamics from the procurement end to the store end, closely monitor inventory levels, and ensure the timely availability of products for stores nationwide. Coordinated Development of Four Major Store Formats; Deepening Community Central Kitchen Strategy and Membership Operations Building a comprehensive channel ecosystem and fully expanding the sales network. Guoquan will firmly advance the coordinated development of four major store formats, namely large stores in townships, large community stores, Guoquan camping stores and Guoquan stir-fry stores; new stores in the second half of the year will predominantly adopt the large-store format, while existing community stores will be strategically upgraded into large-store models. The Company will continue to deepen its presence in county and rural markets, steadily replicate the camping store format and iterate the stir-fry store format, forming a highly efficient comprehensive channel traffic closed loop of "online traffic generation and accumulation, offline conversion and repurchase". Deepening the community central kitchen strategy to expand community consumption scenarios. The Company will continue to deepen the core strategy of "community central kitchen", closely aligning with the all-scenario dining concept of "One Home, Three Tables, Five Meals", build on the enrichment of the core scenarios of hotpot and barbecue, and simultaneously expand into diverse categories such as Chinese and western cuisine, breakfast pastries, bakery and fried foods, drinks and beverages, desserts and ice products and agricultural products, so as to optimise its full-matrix product offerings. Deepening digital and intelligent membership operations to convey the IP value proposition. The Company will empower tiered membership operations with AI intelligent tools to achieve highly personalized and precise reach; improve its membership rights system and membership points mall; and continue to operate the "Guobao" brand IP, leveraging the value of the IP to foster emotional connection with members and enhance their loyalty. Promoting industrial ecosystem synergy and empowering supply chain management with AI. Upholding the "one-product-one-factory" strategy, the Company will activate the synergy advantages of its seven self-owned food ingredient production plants and advance the construction of the food production base in Danzhou, Hainan Province; through digital and intelligent tools such as AI smart production scheduling, big data inventory monitoring, digitalized quality control management, and AI smart routing and order scheduling, it will achieve the precise matching of production with market demand, the efficient allocation of inventory resources, and a rapid response in terminal fulfillment. Deepening the construction of organizational capabilities and empowering franchisee management. Guoquan will further standardize franchisee management, deepen the development of the two major organizations, namely the Franchisee Committee and Store Manager Hubs, and build a standardized and replicable store operation system; it will optimise its training system, cultivate more career-oriented franchisees, and promote synergistic development and mutual benefit between franchisees and the Group. Developing overseas markets in phases to deliver the good taste of China. Guoquan will focus on launching pilot store operations in Hong Kong Special Administrative Region, China, accumulate overseas operational experience through refining localized operations, steadily explore overseas regional markets in a phased manner, and gradually achieve the implementation of its overseas product business. For the full-year 2026 results outlook, Guoquan expects its total store count to exceed 13,100, representing a net addition of over 1,534 stores; new stores in the second half of 2026 will predominantly adopt the large-store format, with an expected closure rate of below 4%; store efficiency is expected to achieve high single-digit growth; and the number of registered members is expected to exceed 95 million. Guoquan forecasts that core operating profit for the year will achieve stable growth.
- Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains MomentumEverest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157% year-on-year to RMB 1.148 billion, driven by continued commercial momentum across the company’s portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency. From the first-half results, the company’s growth drivers are broadening beyond the commercialization of core products to include portfolio expansion, monetization of innovative assets, and global expansion. In the first half of 2026, the company achieved non-IFRS net profit of RMB 97.23 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1.859 billion in cash. Following the reporting period, the company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth. Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said: “Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.” During the period, the company achieved profitability, while expanding its innovative pipeline and advancing its R&D programs. Through continued efforts to strengthen its BD capabilities, the company is developing a model that combines in-licensed and internally developed early-stage assets, exemplified by civorebrutinib (also known as EVER001), with internal incubation and development creating opportunities to out-license innovative assets and realize their value. At the same time, the company is bringing in high-quality mid- to late-stage assets, exemplified by NEFECON(R), while continuing to build its commercialization capabilities and generate further opportunities for BD partnerships. These efforts are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value. Everest’s marketed portfolio continued to gain momentum NEFECON(R) maintained strong sales momentum. In the first half of 2026, sales revenue from NEFECON(R) reached RMB 889 million, with net sales increasing 94% year-on-year. Through deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence, Everest is supporting broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management. Following approval, VELSIPITY(R) moved rapidly into commercialization, with local manufacturing progressing. XERAVA(R) delivered steady hospital sales growth, while local manufacturing advanced as planned. The company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON(R)-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth. Services for mature products under the CSO arrangement commenced in March 2026, generating RMB 145 million in service revenue and RMB 28 million in commercialization profit in the first half of the year. Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said: “In the first half of 2026, the company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients. Our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress. With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets.” EVER001 global licensing deal expected to accelerate overseas development In June, the company entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001) in all markets outside China and certain countries in East and Southeast Asia. The deal has a total potential value of up to $1.1425 billion, including an upfront payment of $112.5 million and up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. CICC believes the partnership is expected to accelerate the global clinical development and commercialization of EVER001 and could advance its development in membranous nephropathy. BOCOM International is positive on EVER001’s overseas market potential and its development opportunities across additional indications. EVER001 achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN. BD expansion further strengthens the product pipeline The company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin(R) strengthened its nephrology and autoimmune portfolio; CARDAMYST(R) and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio. With multiple assets moving through key regulatory and commercialization milestones, the company is building a diversified portfolio of future growth drivers. CARDAMYST(R) is expected to receive approval in the third quarter of 2026, LEROCHOL(R) and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028. In-house R&D and pan-Asia-Pacific expansion advance The company’s in-house R&D also translated into clinical progress. The company’s proprietary AI+mRNA platform also advanced, with its personalized mRNA cancer vaccine EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the company’s in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings. The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the company’s global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the company’s proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products. Meanwhile, CBC Group and the company’s Directors have collectively purchased 5.163 million shares since December 2025, with the transactions totaling more than HK$172.5 million, demonstrating their confidence in the company’s strategic direction and long-term prospects. Overall, Everest Medicines is gradually developing a growth model built on the commercialization of core products, portfolio expansion through BD, a pipeline of innovative assets generated through in-house R&D, and international expansion through global partnerships and its pan-Asia-Pacific platform. As the company enters its new phase, the coordinated strengthening of its capabilities in innovation resource integration, commercialization, and global development is expected to provide an important foundation for future growth.
- Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains MomentumEverest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157% year-on-year to RMB 1.148 billion, driven by continued commercial momentum across the company’s portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency. From the first-half results, the company’s growth drivers are broadening beyond the commercialization of core products to include portfolio expansion, monetization of innovative assets, and global expansion. In the first half of 2026, the company achieved non-IFRS net profit of RMB 97.23 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1.859 billion in cash. Following the reporting period, the company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth. Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said: “Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.” During the period, the company achieved profitability, while expanding its innovative pipeline and advancing its R&D programs. Through continued efforts to strengthen its BD capabilities, the company is developing a model that combines in-licensed and internally developed early-stage assets, exemplified by civorebrutinib (also known as EVER001), with internal incubation and development creating opportunities to out-license innovative assets and realize their value. At the same time, the company is bringing in high-quality mid- to late-stage assets, exemplified by NEFECON(R), while continuing to build its commercialization capabilities and generate further opportunities for BD partnerships. These efforts are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value. Everest’s marketed portfolio continued to gain momentum NEFECON(R) maintained strong sales momentum. In the first half of 2026, sales revenue from NEFECON(R) reached RMB 889 million, with net sales increasing 94% year-on-year. Through deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence, Everest is supporting broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management. Following approval, VELSIPITY(R) moved rapidly into commercialization, with local manufacturing progressing. XERAVA(R) delivered steady hospital sales growth, while local manufacturing advanced as planned. The company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON(R)-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth. Services for mature products under the CSO arrangement commenced in March 2026, generating RMB 145 million in service revenue and RMB 28 million in commercialization profit in the first half of the year. Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said: “In the first half of 2026, the company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients. Our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress. With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets.” EVER001 global licensing deal expected to accelerate overseas development In June, the company entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001) in all markets outside China and certain countries in East and Southeast Asia. The deal has a total potential value of up to $1.1425 billion, including an upfront payment of $112.5 million and up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. CICC believes the partnership is expected to accelerate the global clinical development and commercialization of EVER001 and could advance its development in membranous nephropathy. BOCOM International is positive on EVER001’s overseas market potential and its development opportunities across additional indications. EVER001 achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN. BD expansion further strengthens the product pipeline The company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin(R) strengthened its nephrology and autoimmune portfolio; CARDAMYST(R) and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio. With multiple assets moving through key regulatory and commercialization milestones, the company is building a diversified portfolio of future growth drivers. CARDAMYST(R) is expected to receive approval in the third quarter of 2026, LEROCHOL(R) and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028. In-house R&D and pan-Asia-Pacific expansion advance The company’s in-house R&D also translated into clinical progress. The company’s proprietary AI+mRNA platform also advanced, with its personalized mRNA cancer vaccine EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the company’s in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings. The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the company’s global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the company’s proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products. Meanwhile, CBC Group and the company’s Directors have collectively purchased 5.163 million shares since December 2025, with the transactions totaling more than HK$172.5 million, demonstrating their confidence in the company’s strategic direction and long-term prospects. Overall, Everest Medicines is gradually developing a growth model built on the commercialization of core products, portfolio expansion through BD, a pipeline of innovative assets generated through in-house R&D, and international expansion through global partnerships and its pan-Asia-Pacific platform. As the company enters its new phase, the coordinated strengthening of its capabilities in innovation resource integration, commercialization, and global development is expected to provide an important foundation for future growth.
- Yunfu Wayon Stone Co., LtdWayon Stone Named China's Top 10 Quartz Stone Brands in 2026, Expanding Architectural Surface Solutions for Global ProjectsThe China-based manufacturer — Wayon Stone, was named China's Top 10 Quartz Stone Brands in 2026. This prestigious accolade highlights Wayon's four-decade commitment to material innovation, industrial-scale manufacturing, and its pioneering...